Latest Medical Devices News

Uscom Limited’s shares have been suspended from trading on the ASX due to concerns over its financial health, following a critical auditor’s disclaimer. The suspension will remain until the company meets regulatory requirements.

EMVision Medical Devices launches a $2 million Share Purchase Plan offering shares at a 16.4% discount, bundled with free options exercisable at $3.40, aiming to bolster clinical and commercial milestones.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

EMVision Medical Devices has initiated a unique pre-hospital study in Melbourne to test its First Responder Brain Scanner within one of the world’s few Mobile Stroke Units, aiming to enhance stroke diagnosis and accelerate commercialisation.

Micro-X Ltd has secured a $4.4 million Australian Government grant to develop and trial a portable Head CT scanner designed for standard ambulances, aiming to transform emergency stroke care with faster diagnosis and treatment.

EBR Systems has secured final CMS approval for Transitional Pass-Through reimbursement for its WiSE CRT System, effective October 1, 2025, enhancing hospital adoption prospects in the U.S.

ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.

ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.

Memphasys Limited has secured $0.84 million through a placement and announced a rights issue to raise up to $1.12 million, sharply cutting operating costs to accelerate commercialisation and manufacturing scale-up of its Felix™ bioseparation system.

Cochlear Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 2.15 per share for the first half of 2025, with payments available in multiple currencies based on shareholder location.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.